VSTM peer analysis
Verastem (VSTM) against its competitors: price, today's move, 1-year return and market value side by side.
VSTM and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ACRV Acrivon Therapeutics | $1.57 | -9.77% | -22.66% | – |
| ANL Adlai Nortye | $10.27 | 6.10% | 591.38% | – |
| BBOT BridgeBio Oncology | $2.08 | -4.15% | -82.42% | – |
| CCCC C4 Therapeutics | $3.14 | 6.44% | 33.33% | – |
| CRDF Cardiff Oncology | $0.76 | -13.07% | -66.28% | $58.76M |
| FHTX Foghorn Therapeutics | $1.87 | -1.84% | -52.75% | – |
| IMRX Immuneering | $3.61 | 7.12% | -44.93% | – |
| NUVB Nuvation Bio | $4.19 | 0.00% | -14.23% | – |
| ORIC Oric | $8.82 | 3.89% | -29.68% | $880.01M |
| PRLD Prelude Therapeutics | $3.60 | 1.27% | 158.27% | – |
| VSTM Verastem | $8.40 | -10.45% | 3.06% | $1.14B |
- VSTM's peers: ACRV (Acrivon Therapeutics), ANL (Adlai Nortye), BBOT (BridgeBio Oncology), CCCC (C4 Therapeutics), CRDF (Cardiff Oncology), FHTX (Foghorn Therapeutics), IMRX (Immuneering), NUVB (Nuvation Bio).
Updated 2026-11-07 11:53 UTC